

Company Overview

Acasti is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases. The Company's novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery – all which could help to increase treatment compliance and improve patient outcomes.

The Company's three lead clinical assets have all been granted Orphan Drug Designation by the FDA providing seven years of marketing exclusivity post-launch in the United States and are protected by over 40 granted and pending patents. The lead assets target underserved orphan diseases: (i) GTX-104, an intravenous infusion targeting Subarachnoid Hemorrhage (SAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; (ii) GTX-102, an oral mucosal spray targeting Ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability, for which no treatment currently exists; and (iii) GTX-101, a topical spray, targeting Postherpetic Neuralgia (PHN), a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles), which may persist for months and even years.

Acasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in Japan

Oct 6 2021, 12:00 AM EDT

Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company's Lead Drug Candidate for the Treatment of Subarachnoid Hemorrhage

Sep 27 2021, 12:00 AM EDT

Stock Overview

Symbol ACST
Exchange Nasdaq
Market Cap 74.4m
Last Price \$1.68
52-Week Range \$1.36 - \$9.76

10/22/2021 04:00 PM EDT

Investor Relations

Crescendo Communications, LLC
Chrysler Building - 405 Lexington Ave
9th Floor, Suite 9034
New York, NY 10174
T: 212-671-1020
ACST@crescendo-ir.com

Management Team

Jan D'Alvise

President and CEO

Pierre Lemieux, Ph.D.

Chief Operating and Scientific Officer, Co-Founder

Brian D. Ford CPA-CA

Chief Financial Officer

Dr. George Kottayil

Chief Operating Officer US

Prashant Kohli

VP, Commercial Operations

Acasti Pharma Inc.

3009 Boul. de la Concorde E.
Suite 102
Laval, Québec H7E 2B5
Canada

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.